A Study of BGM0504 Injection in Participants with Obesity or Overweight

Inclusion Criteria:

• A male or female aged 18 to 65 years inclusive at screening

• BMI≥28 kg/m², or 24.0≤BMI<28.0 kg/m² and previous diagnosis with at least one of thefollowing comorbidities: i. Prediabetes (impaired fasting blood glucose and/orimpaired glucose tolerance), hypertension, nonalcoholic fatty liver disease, or oneor more of these; ii. Joint pain with weight bearing; iii. Dyspnea caused by obesityor obstructive sleep apnea syndrome

• Weight change < 5.0% (chief complaint) after diet and exercise control for at least 12 weeks before screening

• Female participants who are not pregnant or lactating. Female participants withchildbearing potential and their partners should use highly effective, medicallyaccepted contraception, will not have pregnancy and fertility plan, and refrain fromdonating ovum until one month after the end of the study

Exclusion Criteria:

• Diabetes mellitus

• Known to be allergic to 3 or more kinds of foods or medications, or allergic toGLP-1 agonist, or have a severe allergic disease (asthma, urticaria, eczematousdermatitis, etc.) at screening

• Has been treated with GLP-1 receptor agonists or similar drugs containing the sametarget, or drugs used for weight control in the three months prior to screening

• Secondary disease or drug-induced obesity, including : elevated cortisol (e.g.Cushing's syndrome), obesity due to pituitary and hypothalamic damage, obesity dueto diet drug reduction/discontinuation, etc.;

• History of pancreatitis

• Have the currently uncontrolled thyroid diseases with stable treatment dose andclinically significant abnormal results of thyroid function test occurred atscreening

• Previous history of moderate or severe depression, or PHQ-9 score ≥15, or history ofother serious mental illness, or Any lifetime history of a suicide attempt